Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Lung Cancer
86%
Tumor
60%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
42%
Chemotherapy
29%
Overall Survival
29%
Dendritic Cells
26%
Insulin-like
21%
Insulin-like Growth Factor 1 Receptor (IGF1R)
21%
Growth Factors
20%
Small Cell Lung Cancer
19%
Adenovirus
17%
Non-small Cell Lung Cancer Patients
17%
Immune Checkpoint Inhibitors
16%
Vascular Endothelial Growth Factor
16%
Tumor Cells
16%
Erlotinib
16%
Paclitaxel
15%
In Cancer
15%
Programmed Death-ligand 1 (PD-L1)
15%
Resectable Lung Cancer
14%
Lung Cancer Treatment
14%
Phase II Trial
12%
Mutant p53
12%
Confidence Interval
12%
Clinical Trials
11%
Tumor Growth
11%
CheckMate
11%
Continuous Infusion
11%
Radiation Therapy
11%
Cancer Patients
11%
Nivolumab Plus Ipilimumab
11%
International Association for the Study of Lung Cancer (IASLC)
11%
Human Lung Cancer
10%
Hazard Ratio
10%
EGFR mutation
10%
Targeted Therapy
10%
NOTCH3
10%
Metastatic Non-small Cell Lung Cancer
10%
Lung Adenocarcinoma
10%
Lung Cancer Cell Lines
9%
Phase I Study
9%
TP53 mutation
9%
Lung Cancer Patients
9%
Clinical Outcomes
9%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
9%
Cytotoxic T Lymphocytes
9%
Locally Advanced
9%
Phase II Study
8%
KRAS mutation
8%
Medicine and Dentistry
Non Small Cell Lung Cancer
94%
Lung Cancer
88%
Neoplasm
63%
Malignant Neoplasm
40%
Overall Survival
28%
Immunotherapy
22%
Chemotherapy
21%
Disease
20%
Epidermal Growth Factor Receptor
20%
Small Cell Lung Cancer
17%
Nivolumab
17%
Biological Marker
16%
Non-Small Cell Lung Cancer
16%
Protein P53
14%
Targeted Therapy
13%
Ipilimumab
13%
Sodium Fluoride
11%
Lung Adenocarcinoma
11%
Lung
11%
Proteomics
11%
Programmed Death 1 Ligand 1
11%
Dendritic Cell
10%
Immune Checkpoint Inhibitor
10%
Radiation Therapy
9%
Notch
9%
Cancer Cell
8%
Progression Free Survival
8%
Hazard Ratio
8%
Arm
7%
Adenoviridae
7%
Lung Cancer Cell Line
7%
Chemoradiotherapy
7%
Brain Metastasis
6%
Somatomedin C Receptor
6%
Atezolizumab
6%
Health Care Cost
6%
Oncology
6%
Metastatic Carcinoma
6%
Clinical Trial
6%
Immune Response
6%
Receptor
6%
Recurrent Disease
6%
Messenger RNA
5%
Primary Tumor
5%
Exon
5%
Cell Line
5%
Surgery
5%
Gene Mutation
5%
Adverse Event
5%
Immunity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
89%
Lung Cancer
71%
Neoplasm
59%
Malignant Neoplasm
41%
Chemotherapy
35%
Overall Survival
26%
Somatomedin C Receptor
22%
Disease
20%
Epidermal Growth Factor Receptor
18%
Paclitaxel
17%
Somatomedin
17%
Immunotherapy
17%
Protein P53
15%
Small Cell Lung Cancer
14%
Nivolumab
14%
Adenoviridae
14%
Biological Marker
13%
Erlotinib
12%
Receptor
12%
Immune Checkpoint Inhibitor
11%
Adverse Event
10%
Vasculotropin
10%
Ipilimumab
10%
Programmed Death 1 Ligand 1
10%
Progression Free Survival
9%
Sodium Fluoride
9%
Chemoradiation Therapy
9%
Clinical Trial
8%
Digestive System Cancer
8%
Carboplatin
8%
Bevacizumab
7%
Docetaxel
7%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%
Protein Tyrosine Kinase Inhibitor
6%
Tumor Growth
6%
Solid Malignant Neoplasm
6%
Combination Therapy
6%
Tumor Suppressor Protein
5%
Recurrent Disease
5%
Adenocarcinoma
5%
Lung Adenocarcinoma
5%
